Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 105

1.

Cardiac resynchronization therapy is associated with a reduction in ICD therapies as it improves ventricular function.

Galve E, Oristrell G, Acosta G, Ribera-Solé A, Moya-Mitjans À, Ferreira-González I, Pérez-Rodon J, García-Dorado D.

Clin Cardiol. 2018 Mar 31. doi: 10.1002/clc.22958. [Epub ahead of print]

2.

E/e' ratio and left atrial area are predictors of atrial fibrillation in patients with hypertrophic cardiomyopathy.

Costabel JP, Galve E, Terricabras M, Ametrano C, Ronderos R, Baranchuk A, Evangelista A, Avegliano G.

Echocardiography. 2018 Mar 5. doi: 10.1111/echo.13857. [Epub ahead of print]

PMID:
29505666
3.

A risk score to predict the absence of left ventricular reverse remodeling: Implications for the timing of ICD implantation in primary prevention.

Pérez-Rodon J, Galve E, Pérez-Bocanegra C, Soriano-Sánchez T, Recio-Iglesias J, Domingo-Baldrich E, Alzola-Guevara M, Ferreira-González I, Marsal JR, Ribera-Solé A, Gutierrez García-Moreno L, Cruz-Carlos LM, Rivas-Gandara N, Roca-Luque I, Francisco-Pascual J, Evangelista-Masip A, Moya-Mitjans À, García-Dorado D.

J Cardiol. 2018 May;71(5):505-512. doi: 10.1016/j.jjcc.2017.10.019. Epub 2017 Nov 26.

PMID:
29183646
4.

Impact of an osteoporosis specialized unit on bone health in breast cancer survivals treated with aromatase inhibitors.

Martínez P, Galve E, Arrazubi V, Sala MÁ, Fernández S, Pérez CE, Arango JF, Torre I.

Reumatol Clin. 2017 Oct 11. pii: S1699-258X(17)30229-2. doi: 10.1016/j.reuma.2017.08.005. [Epub ahead of print] English, Spanish.

5.

Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.

Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi JL, Ten Berg JM, Steg PG, Hohnloser SH; RE-DUAL PCI Steering Committee and Investigators.

N Engl J Med. 2017 Oct 19;377(16):1513-1524. doi: 10.1056/NEJMoa1708454. Epub 2017 Aug 27.

6.

Consensus document for the use of the Polypill in the secondary prevention of cardiovascular disease.

González-Juanatey JR, Mostaza JM, Lobos JM, Abarca B, Llisterri JL, Baron-Esquivias G, Galve E, Lidón RM, Garcia-Moll FX, Sánchez PL, Suárez C, Millán J, Pallares V, Alemán JJ, Egocheaga I.

Med Clin (Barc). 2017 Feb 9;148(3):139.e1-139.e15. doi: 10.1016/j.medcli.2016.10.031. Epub 2016 Dec 16. English, Spanish.

PMID:
27993410
7.

[Medical expert consensus in AH on the clinical use of triple fixed-dose antihypertensive therapy in Spain].

Mazón P, Galve E, Gómez J, Gorostidi M, Górriz JL, Mediavilla JD; en representación de las Sociedades Españolas de Cardiología, Medicina Interna y Nefrología.

Hipertens Riesgo Vasc. 2016 Oct - Dec;33(4):133-144. doi: 10.1016/j.hipert.2016.03.001. Epub 2016 Apr 27. Spanish.

PMID:
27129628
8.

Insufficient Lipid Control in Patients With Coronary Artery Disease: An Unresolved Problem. Response.

Galve E, Cordero A, Cequier Á, González-Juanatey JR.

Rev Esp Cardiol (Engl Ed). 2016 Oct;69(10):997. doi: 10.1016/j.rec.2016.07.003. Epub 2016 Sep 9. English, Spanish. No abstract available.

PMID:
27623492
9.

Degree of Lipid Control in Patients With Coronary Heart Disease and Measures Adopted by Physicians. REPAR Study.

Galve E, Cordero A, Cequier A, Ruiz E, González-Juanatey JR.

Rev Esp Cardiol (Engl Ed). 2016 Oct;69(10):931-938. doi: 10.1016/j.rec.2016.02.012. Epub 2016 May 11. English, Spanish.

PMID:
27178117
10.

Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens.

Senni M, McMurray JJ, Wachter R, McIntyre HF, Reyes A, Majercak I, Andreka P, Shehova-Yankova N, Anand I, Yilmaz MB, Gogia H, Martinez-Selles M, Fischer S, Zilahi Z, Cosmi F, Gelev V, Galve E, Gómez-Doblas JJ, Nociar J, Radomska M, Sokolova B, Volterrani M, Sarkar A, Reimund B, Chen F, Charney A.

Eur J Heart Fail. 2016 Sep;18(9):1193-202. doi: 10.1002/ejhf.548. Epub 2016 May 12.

11.

[Consensus on objectives and action guidelines on low density lipoproteins-cholesterol control in very high risk cardiovascular patients].

Galve E, Guijarro-Herraiz C, Masana-Marin L, Cordero-Fort A.

Clin Investig Arterioscler. 2016 Jan-Feb;28(1):31-42. doi: 10.1016/j.arteri.2015.09.002. Epub 2015 Dec 3. Spanish.

PMID:
26657097
12.

Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study.

Manso L, Palomo AG, Pérez Carrión R, Cassinello J, Gallegos Sancho I, Chacón López-Muñiz I, Olier C, Fernández-Aramburo A, Llorca C, González X, Llorente R, Torregrosa D, Álvarez I, Gálve E, Bueno C, Garau I, García MJ, González-Santiago S, Ballesteros AI, Blanco E, Galán A, González S, Perelló A, Cortés-Funes H, Grávalos C.

Anticancer Res. 2015 Dec;35(12):6941-50.

PMID:
26637920
13.

Trends in Risk Factors and Treatments in Patients With Stable Ischemic Heart Disease Seen at Cardiology Clinics Between 2006 and 2014.

Cordero A, Galve E, Bertomeu-Martínez V, Bueno H, Fácila L, Alegría E, Cequier Á, Ruiz E, González-Juanatey JR.

Rev Esp Cardiol (Engl Ed). 2016 Apr;69(4):401-7. doi: 10.1016/j.rec.2015.08.011. Epub 2015 Nov 27.

PMID:
26631917
14.

Position statement of the SEMI, SED, redGDPS, SEC, SEEDO, SEEN, SEMERGEN y SEMFYC.

Gómez Huelgas R, Gómez Peralta F, Carrillo Fernández L, Galve E, Casanueva FF, Puig Domingo M, Mediavilla Bravo JJ, Orozco Beltrán D; en nombre del Grupo de Trabajo para el Documento de Consenso «Hacia un manejo integral del paciente con diabetes y obesidad», Muñoz JE, Menéndez Torre E, Artola Menendez S, Mazón Ramos P, Monereo Megías S, Caixas Pedrágos A, López Simarro F, Álvarez Guisasola F.

Rev Clin Esp. 2015 Dec;215(9):505-14. doi: 10.1016/j.rce.2015.07.003. Epub 2015 Sep 9. English, Spanish.

PMID:
26363771
15.

Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile.

González-Martín A, Alba E, Ciruelos E, Cortés J, Llombart A, Lluch A, Andrés R, Álvarez I, Aramendía JM, de la Peña FA, Barnadas A, Batista N, Calvo L, Galve E, García-Palomo A, García-Sáenz JÁ, de la Haba J, López R, López-Vivanco G, Martínez-Jáñez N, de Dueñas EM, Plazaola A, Rodríguez-Lescure Á, Ruiz M, Sánchez-Rovira P, Santaballa A, Seguí MÁ, Tusquets I, Zamora P, Martín M.

Curr Cancer Drug Targets. 2016;16(5):415-28. Review.

PMID:
26278712
16.

[Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology Position Statement on Dyslipidemia Management. Differences Between the European and American Guidelines].

Lobos Bejarano JM, Galve E, Royo-Bordonada MÁ, Alegría Ezquerra E, Armario P, Brotons Cuixart C, Camafort Babkowski M, Cordero Fort A, Maiques Galán A, Mantilla Morató T, Pérez Pérez A, Pedro-Botet J, Villar Álvarez F, González-Juanatey JR; Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology.

Hipertens Riesgo Vasc. 2015 Apr-Jun;32(2):83-91. doi: 10.1016/j.hipert.2014.09.002. Epub 2014 Nov 14. Spanish.

PMID:
26179969
17.

[Changing the paradigm: valsartan-inhibitor of neprilysin, a new dual-acting drug for arterial hypertension and heart failure].

Galve E, Casas-Masnou G, García-Dorado D.

Hipertens Riesgo Vasc. 2015 Jan-Mar;32(1):1-5. doi: 10.1016/j.hipert.2014.11.001. Epub 2014 Dec 15. Spanish. No abstract available.

PMID:
26179851
18.

Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology Position Statement on Dyslipidemia Management: differences between the European and American Guidelines.

Lobos Bejarano JM, Galve E, Royo-Bordonada MÁ, Alegría Ezquerra E, Armario P, Brotons Cuixart C, Camafort Babkowski M, Cordero Fort A, Maiques Galán A, Mantilla Morató T, Pérez Pérez A, Pedro-Botet J, Villar Álvarez F, González-Juanatey JR; Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention; Spanish Society of Cardiology.

Rev Esp Salud Publica. 2015 Jan-Feb;89(1):15-26. doi: 10.4321/S1135-57272015000100003. English, Spanish.

19.

Importance of sudden cardiac death risk stratification in hypertrophic cardiomyopathy. Response.

Sarrias A, Galve E, Sabaté X, Villuendas R.

Rev Esp Cardiol (Engl Ed). 2015 Jun;68(6):545. doi: 10.1016/j.rec.2015.02.007. Epub 2015 Apr 20. No abstract available.

PMID:
25907859
20.

[Renal denervation as treatment of resistant hypertension].

Galve E, Martell-Claros N, Camafort-Babkowski M; Grupo de consenso español sobre denervación renal.

Med Clin (Barc). 2015 Aug 7;145(3):131-5. doi: 10.1016/j.medcli.2014.12.011. Epub 2015 Mar 4. Spanish. No abstract available.

PMID:
25746610

Supplemental Content

Loading ...
Support Center